Mindfulness based on ?Meta-Inner Humor

Randomized Controlled Trial of a Novel Mindfulness based on ?Meta-Inner Humor for Co-occurrence of Anxiety, OCD, and Depressive Disorders

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130904014564N2

Enrollment

101

Registered

2025-09-04

Start date

2024-07-03

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Generalized Anxiety Disorder. Condition 2: Social Anxiety Disorder. Condition 3: Panic Disorder?. Condition 4: Specific Phobia. Condition 5: Major Depressive Disorder. Condition 6: Dysthymia. Condition 7: Obsessive-compulsive disorder?. Condition 8: Body dysmorphic disorder?. Condition 9: Hoarding disorder. Generalized anxiety disorder Social phobias Panic disorder [episodic paroxysmal anxiety] without agoraphobia Specific (isolated) phobias Major depressive disorder, single ep

Interventions

Intervention 1: Intervention group: Mindfulness based on Meta-Inner Humor. Intervention 2: Intervention group: Placebo-Control Intervention (Attention-Matched Psychoeducational Control)?. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ?(a) Meeting DSM-5 diagnostic criteria for at least one ?disorder in each of the following ?categories—anxiety disorders, depressive disorders, and ?obsessive-compulsive and related ?disorders—as determined by the Structured Clinical Interview ?for DSM-5 (SCID-5); (b) Age 18 ?years or older; (c) Provision of written informed consent. ?

Exclusion criteria

Exclusion criteria: Exclusion criteria were: (a) ?current or past diagnosis of psychotic disorders, bipolar ?disorders, severe personality disorders, ?substance use disorders, or any debilitating medical ?condition (e.g., uncontrolled chronic ?illness); (b) Current suicidality. Use of stable pharmacotherapy (e.g., SSRIs, SNRIs, ?benzodiazepines) was permitted if dosage remained unchanged during the six months prior to ?enrollment and throughout the intervention.?

Design outcomes

Primary

Measure	Time frame
Obsessive compulsive symptoms. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: The Obsessive-Compulsive Inventory-Revised (OCI-R)?.;Depressive symptom. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: Patient Health Questionnaire–9 (PHQ-9)?.;Trait anxiety ?. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: State-Trait Anxiety Inventory (STAI)?.;Life satisfaction?. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: Satisfaction with Life Scale (SWLS)?.	—

Measure

Time frame

Obsessive compulsive symptoms. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: The Obsessive-Compulsive Inventory-Revised (OCI-R)?.;Depressive symptom. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: Patient Health Questionnaire–9 (PHQ-9)?.;Trait anxiety ?. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: State-Trait Anxiety Inventory (STAI)?.;Life satisfaction?. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and at 6-month follow-up?. Method of measurement: Satisfaction with Life Scale (SWLS)?.

—

Secondary

Measure	Time frame
Mindfulness. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: The Mindfulness Attention Awareness Scale (MAAS)?.;Psychological inflexibility. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Acceptance and Action Questionnaire–II (AAQ-II)?.;Repetitive negative thoughts. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Repetitive Thinking Questionnaire–10 (RTQ-10)?.;Positive and negative metacognitions. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Metacognitions Questionnaire–30 (MCQ-30)?.;Self-Compassion. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Self-Compassion Scale–Short Form (SCS-SF)?.	—

Measure

Time frame

Mindfulness. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: The Mindfulness Attention Awareness Scale (MAAS)?.;Psychological inflexibility. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Acceptance and Action Questionnaire–II (AAQ-II)?.;Repetitive negative thoughts. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Repetitive Thinking Questionnaire–10 (RTQ-10)?.;Positive and negative metacognitions. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Metacognitions Questionnaire–30 (MCQ-30)?.;Self-Compassion. Timepoint: Pre-treatment (baseline), post-treatment (end of week 10), and a six-month follow-up?. Method of measurement: Self-Compassion Scale–Short Form (SCS-SF)?.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Akbari

Kharazmi University

m.akbari@khu.ac.ir+98 21 8832 9220

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026